Ibarra-Arzamendia Patricia N, Hanly Mark G
Department of Pathology, Hospital Central de IPS, Asuncion 1741, Paraguay.
Department of Pathology, Baptist MD Anderson Cancer Center, Jacksonville FL 31522, USA.
Case Rep Pathol. 2020 Jan 29;2020:6918093. doi: 10.1155/2020/6918093. eCollection 2020.
The use of nonsaline injectable lifting agents is now routine in the performance of endoscopic mucosal resection of bowel neoplasms (EMR). These agents are used to elevate the mucosa from the muscularis propria and permit more a complete resection of the lesion while mitigating risk of possible thermal injury to the bowel wall and thus preventing perforation. After injection, these new agents, which are replacing normal saline, often remain present in the tissues for some time following the procedure and may be identified in the resection specimens where they may mimic a number of other conditions such as mucin pools, lymphangiomas, granulomatous inflammation, and amyloid deposition. We describe the histological findings associated with the use of nonsaline injectable mucosal lifting agents. Awareness of these agents and their associated artefact may reduce misdiagnosis or the use of unnecessary ancillary studies and highlights the importance of proving relevant clinical information on submission of specimens for pathological examination.
在肠道肿瘤内镜黏膜切除术（EMR）中，使用非盐水注射性提升剂现已成为常规操作。这些药剂用于将黏膜从固有肌层抬起，以便更完整地切除病变，同时降低肠壁可能受到热损伤的风险，从而防止穿孔。注射后，这些取代生理盐水的新型药剂在术后通常会在组织中留存一段时间，并且在切除标本中可能被识别出来，它们可能会模仿许多其他情况，如黏液池、淋巴管瘤、肉芽肿性炎症和淀粉样沉积。我们描述了与使用非盐水注射性黏膜提升剂相关的组织学发现。了解这些药剂及其相关假象可能会减少误诊或不必要的辅助检查的使用，并突出了在提交标本进行病理检查时提供相关临床信息的重要性。
